Vetr Inc. announced Acorda Therapeutics Inc (NASDAQ:ACOR), boosting its stock price target to $30.58 today
- Updated: March 19, 2017
In a report released on 03/20/2017 Vetr Inc. increased the stock price target of Acorda Therapeutics Inc (NASDAQ:ACOR) to $30.58 stating a potential upside of 0.14%.
On 3/14/2017, Vetr Inc. released a statement for Acorda Therapeutics Inc (NASDAQ:ACOR) bumped up the target price from $0.00 to $30.58 that suggested an upside of 0.08%.
Boasting a price of $26.85, Acorda Therapeutics Inc (NASDAQ:ACOR) traded -3.07% lower on the day. With the last stock price close up 21.72% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Acorda Therapeutics Inc has recorded a 50-day average of $25.05 and a two hundred day average of $22.06. Trade Volume was up over the average, with 1,628,484 shares of ACOR changing hands over the typical 852,903
With a total market value of $0, Acorda Therapeutics Inc has with a one year low of $16.40 and a one year high of $33.00 .
A total of 5 brokers have issued a research note on the company. 1 broker rating the stock a strong buy, 3 brokers rating the stock a buy, 4 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $47.20.
Brief Synopsis On Acorda Therapeutics Inc (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.